Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Pharmosa Biopharm's Enterprise Value for the quarter that ended in Jun. 2026 was NT$4,381.15 Mil.
Pharmosa Biopharm's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-348.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmosa Biopharm EV-to-EBIT Related Terms
Pharmosa Biopharm EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Pharmosa Biopharm's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6875 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Pharmosa Biopharm's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmosa Biopharm EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmosa Biopharm's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Pharmosa Biopharm's EV-to-EBIT falls into.
Pharmosa Biopharm's current Enterprise Value is NT$3,580.21 Mil.
Pharmosa Biopharm's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-348.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmosa Biopharm (ROCO:6875) has a EV-to-EBIT of -10.27 as of Sep. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pharmosa Biopharm and its competitors. According to the industry distribution chart, Pharmosa Biopharm ranks #999999 out of 365 companies in the Biotechnology industry.
Is Pharmosa Biopharm's EV-to-EBIT too high?
Pharmosa Biopharm's current EV-to-EBIT is -10.27. Based on the distribution chart, Pharmosa Biopharm ranks #999999 out of 365 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharmosa Biopharm has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmosa Biopharm's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmosa Biopharm ranks #999999 out of 365 companies for EV-to-EBIT. This places Pharmosa Biopharm in the lower half of its industry. The industry median EV-to-EBIT is 15.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.65, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pharmosa Biopharm and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmosa Biopharm's current EV-to-EBIT is -10.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmosa Biopharm stock overvalued right now?
Based on GuruFocus' analysis, Pharmosa Biopharm (ROCO:6875) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$15.32, compared to a current price of NT$32.30 — trading 110.8% above its estimated fair value. The current EV-to-EBIT is -10.27. Pharmosa Biopharm's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Pharmosa Biopharm (ROCO:6875), the current EV-to-EBIT is -10.27 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmosa Biopharm (ROCO:6875) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmosa Biopharm stock appears to be overvalued.
The current stock price of NT$32.30 is trading 110.8% above its estimated GF Value™ of NT$15.32.
GuruFocus considers Pharmosa Biopharm to be Significantly Overvalued.
Key valuation signals for ROCO:6875:
EV-to-EBIT: -10.27
GF Value™: NT$15.32 vs. price of NT$32.30 (110.8% above fair value)
No single metric tells the full story. See the ROCO:6875 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmosa Biopharm Inc is a world-class biotechnology company. The Company's principal business activities comprise the development and commercialization of inventive biopharmaceutical drugs. Its product portfolio includes sustained-release dosage forms and drug-device combination products intended for home based therapies.
27GF Score
Get the complete analysis for ROCO:6875
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6875 has been successfully added to your 
